Cargando…

Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series

Objective: The apoptotic and cytotoxic effects of arsenic trioxide (ATO) makes it a potentially suitable agent for the treatment of patients with neuroblastoma with poor prognosis; therefore, we try to evaluate the effectiveness and safety of ATO combined with reinduction/induction chemotherapy in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Feng, Chuchu, Chen, Yantao, Huang, Ke, Li, Chunmou, Xiong, Xilin, Li, Peng, Zhou, Dunhua, Peng, Xiaomin, Weng, Wenjun, Deng, Xiaogeng, Wu, Yaohao, Fang, Jianpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485563/
https://www.ncbi.nlm.nih.gov/pubmed/34569870
http://dx.doi.org/10.1177/15330338211041454
_version_ 1784577561511067648
author Li, Yang
Feng, Chuchu
Chen, Yantao
Huang, Ke
Li, Chunmou
Xiong, Xilin
Li, Peng
Zhou, Dunhua
Peng, Xiaomin
Weng, Wenjun
Deng, Xiaogeng
Wu, Yaohao
Fang, Jianpei
author_facet Li, Yang
Feng, Chuchu
Chen, Yantao
Huang, Ke
Li, Chunmou
Xiong, Xilin
Li, Peng
Zhou, Dunhua
Peng, Xiaomin
Weng, Wenjun
Deng, Xiaogeng
Wu, Yaohao
Fang, Jianpei
author_sort Li, Yang
collection PubMed
description Objective: The apoptotic and cytotoxic effects of arsenic trioxide (ATO) makes it a potentially suitable agent for the treatment of patients with neuroblastoma with poor prognosis; therefore, we try to evaluate the effectiveness and safety of ATO combined with reinduction/induction chemotherapy in children with recurrent/refractory or newly diagnosed stage 4 neuroblastoma. Methods: Retrospective analysis was performed on seven pediatric patients with recurrent /refractory or newly diagnosed stage 4 neuroblastoma treated with traditional reinduction/induction chemotherapy combined with ATO. Results: A total of 7 patients were treated synchronously with ATO and chemotherapy for up to nine courses; all patients received conventional chemotherapy plus a 0.16 mg/kg/day dose of intravenous ATO during reinduction/induction chemotherapy. Treatment was effective in five patients and ineffective in the other two patients. The overall response rate was 71.43% (5 of 7). The side effects of the ATO combination were minor, whereby only treatment in one patient was terminated at the sixth course due to a prolonged QT interval (0.51 s), which returned to normal after symptomatic treatment. Conclusions: ATO can be safely and effectively combined with chemotherapy drugs as a potential alternative means of treatment for high-risk stage 4 neuroblastoma, and we have observed that ATO can restore the sensitivity of chemotherapy in some patients who were resistant to previous chemotherapy. Further investigations and clinical data are required to confirm these observations.
format Online
Article
Text
id pubmed-8485563
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84855632021-10-02 Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series Li, Yang Feng, Chuchu Chen, Yantao Huang, Ke Li, Chunmou Xiong, Xilin Li, Peng Zhou, Dunhua Peng, Xiaomin Weng, Wenjun Deng, Xiaogeng Wu, Yaohao Fang, Jianpei Technol Cancer Res Treat Original Article Objective: The apoptotic and cytotoxic effects of arsenic trioxide (ATO) makes it a potentially suitable agent for the treatment of patients with neuroblastoma with poor prognosis; therefore, we try to evaluate the effectiveness and safety of ATO combined with reinduction/induction chemotherapy in children with recurrent/refractory or newly diagnosed stage 4 neuroblastoma. Methods: Retrospective analysis was performed on seven pediatric patients with recurrent /refractory or newly diagnosed stage 4 neuroblastoma treated with traditional reinduction/induction chemotherapy combined with ATO. Results: A total of 7 patients were treated synchronously with ATO and chemotherapy for up to nine courses; all patients received conventional chemotherapy plus a 0.16 mg/kg/day dose of intravenous ATO during reinduction/induction chemotherapy. Treatment was effective in five patients and ineffective in the other two patients. The overall response rate was 71.43% (5 of 7). The side effects of the ATO combination were minor, whereby only treatment in one patient was terminated at the sixth course due to a prolonged QT interval (0.51 s), which returned to normal after symptomatic treatment. Conclusions: ATO can be safely and effectively combined with chemotherapy drugs as a potential alternative means of treatment for high-risk stage 4 neuroblastoma, and we have observed that ATO can restore the sensitivity of chemotherapy in some patients who were resistant to previous chemotherapy. Further investigations and clinical data are required to confirm these observations. SAGE Publications 2021-09-27 /pmc/articles/PMC8485563/ /pubmed/34569870 http://dx.doi.org/10.1177/15330338211041454 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Li, Yang
Feng, Chuchu
Chen, Yantao
Huang, Ke
Li, Chunmou
Xiong, Xilin
Li, Peng
Zhou, Dunhua
Peng, Xiaomin
Weng, Wenjun
Deng, Xiaogeng
Wu, Yaohao
Fang, Jianpei
Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title_full Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title_fullStr Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title_full_unstemmed Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title_short Improved Outcomes with Induction Chemotherapy Combined with Arsenic Trioxide in Stage 4 Neuroblastoma: A Case Series
title_sort improved outcomes with induction chemotherapy combined with arsenic trioxide in stage 4 neuroblastoma: a case series
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485563/
https://www.ncbi.nlm.nih.gov/pubmed/34569870
http://dx.doi.org/10.1177/15330338211041454
work_keys_str_mv AT liyang improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT fengchuchu improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT chenyantao improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT huangke improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT lichunmou improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT xiongxilin improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT lipeng improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT zhoudunhua improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT pengxiaomin improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT wengwenjun improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT dengxiaogeng improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT wuyaohao improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries
AT fangjianpei improvedoutcomeswithinductionchemotherapycombinedwitharsenictrioxideinstage4neuroblastomaacaseseries